- Details
- Alicia Morgans engages with Michael Morris to delve into the rapidly evolving landscape of radiopharmaceuticals in prostate cancer treatment, highlighting the significance of the VISION data and existing therapies like radium-223. Dr. Morris outlines that the abundance of radiopharmaceutical tools is a "good problem to have," emphasizing that these agents are not one-size-fits-all but have unique...
|
- Details
- In an educational session at the 2021 ASCO annual meeting titled Beyond the Androgen Receptor: New Avengers in the Treatment of Castrate-Resistant Metastatic Cancer, Mark Fleming, MD presented on treatment sequencing in castrate-resistant metastatic cancer (CRPC). In this conversation with Charles Ryan, MD, he speaks to the complex therapeutic landscape and offers guidance in managing treatment se...
|
- Details
- Neeraj Agarwal, MD joins Petros Grivas, MD, PhD, sharing his clinical perspective on using relugolix in patients with advanced prostate cancer, and how this new oral treatment option fits into the prostate cancer treatment algorithm. The phase 3 HERO trial looked at patients with advanced prostate cancer, locally advanced prostate cancer, as well as metastatic prostate cancer, and patients were ra...
|
- Details
- Advanced Nurse Practitioner, Brenda Martone of Northwestern University Feinberg School of Medicine joins Alicia Morgans, MD, MPH in a discussion on operationalizing the use of the oral GnRH antagonist, relugolix, in clinical practice. They discuss the unique challenges often faced with getting an oral treatment into the patient's hands and talk through the best practices to ensure a successful pro...
|
- Details
- In this conversation Alicia Morgans, MD, MPH, and Ashley Ross, MD discuss his considerations of patient selection when using the oral GnRH antagonist, relugolix. Dr. Ross explains his thought process when considering oral ADT therapy for his patients, and outlines three specific scenarios when he leans into recommending its use for his patients and his approach to patient follow-up once oral treat...
|
- Details
- In a comprehensive discussion led by Charles Ryan, James Gulley delves into the role of genomic testing and immunotherapy in treating prostate cancer. Dr. Gulley emphasizes the importance of personalized treatment, highlighting studies that identify specific genomic markers like homologous recombination deficiency and mismatch repair deficiency. These markers can guide the use of targeted therapie...
|
- Details
- In this UroToday Journal Club, Christopher Wallis and Zachary Klaassen discuss the recently published article in the Lancet Oncology, "Stereotactic ablative body radiotherapy in patients with oligometastatic cancers: A prospective, registry-based, single-arm, observational, evaluation study." Patients with oligometastatic disease have a more favorable prognosis than those with widespread metastati...
|
- Details
- The United States Food and Drug Administration (FDA) approved Orgovyx (relugolix), the first and only oral GnRH receptor antagonist for the treatment of patients with advanced prostate cancer. Alicia Morgans, MD, MPH, and Charles Ryan, MD discuss Orgovyx and what it means to men being treated for advanced prostate cancer who now have an oral ADT treatment option. The FDA approval of Orgovyx is bas...
|
- Details
- Speaking with Alicia Morgans, Karim Fizazi discusses the final overall survival analysis of the PROSPER study in nonmetastatic castration-resistant prostate cancer. Enzalutamide has previously been shown to postpone the time to metastasis or death. Data presented at ASCO 2020 demonstrated that overall survival is significantly improved in patients receiving enzalutamide — median overall survival w...
|
- Details
- Fred Saad joins Alicia Morgans to discuss the updated data from the PROSPER trial of enzalutamide for nonmetastatic castration-resistant prostate cancer. The updated results show that enzalutamide not only improves metastasis-free-survival, as was indicated by the results published in 2018 but also significantly extends overall survival. Biographies: Fred Saad, MD, FRCS, Professor and Chief of Uro...
|